Mineralys Therapeutics, Inc. (MLYS)
28.94
-0.10
(-0.34%)
USD |
NASDAQ |
Sep 03, 12:49
Mineralys Therapeutics Research and Development Expense (TTM) : 301.59M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 301.59M |
| March 31, 2026 | 118.50M |
| December 31, 2025 | 132.01M |
| September 30, 2025 | 152.18M |
| June 30, 2025 | 174.71M |
| March 31, 2025 | 175.71M |
| December 31, 2024 | 168.58M |
| September 30, 2024 | 147.70M |
| Date | Value |
|---|---|
| June 30, 2024 | 116.21M |
| March 31, 2024 | 88.82M |
| December 31, 2023 | 70.36M |
| September 30, 2023 | 54.49M |
| June 30, 2023 | 38.05M |
| March 31, 2023 | 31.76M |
| December 31, 2022 | 26.25M |
| September 30, 2022 | 25.05M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| MapLight Therapeutics, Inc. | 198.70M |
| Evommune, Inc. | 83.77M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |